September 13, 2019PressReleasePoint
Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta And Herceptin Using Halozyme's Enhanze Drug Delivery Technology
New Subcutaneous Fixed-dose Combination Significantly Reduced Administration Time - - Data to be Subm... See more »